Sequenom Inc, a life sciences company providing genetic analysis solutions, has come to an agreement with MultiPlan Inc, a provider of health care cost management solutions (PHCS). Under this expanded agreement, Sequenom’s participation in the PHCS and MultiPlan networks will now include its Center for Molecular Medicine’s MaterniT21 PLUS™ laboratory-developed test to detect certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal abnormalities.

The MaterniT21 PLUS test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation. In the US, there are an estimated 750,000 such high-risk pregnancies each year. Results of the MaterniT21 PLUS test delivered to ordering physicians will include the presence of any of the three trisomies for their high-risk patients. The MaterniT21 PLUS test is available through Sequenom CMM as a testing service to physicians.

Source: Sequenom Inc